Clinical trials: Nivolumab
Non-Clear Cell Renal Cell Carcinoma
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
This is a multicenter, randomized (2:1), open-label, controlled Phase 3 trial of XL092 in combination with nivolumab versus sunitinib in subjects with unresectable, locally advanced or metastatic nccRCC who have not received…
- Trial name
- STELLAR-304 (NCT05678673)
- Testing
- XL092, Nivolumab, Sunitinib Malate
- Where
- 163 sites in United States, Argentina and 23 more
- Volunteers
- 317 people
- Sponsor
- Exelixis
Progressive Glioblastoma, Recurrent Glioblastoma
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
This phase II trial compares the safety, side effects and effectiveness of anti-lag-3 (relatlimab) and anti-PD-1 blockade (nivolumab) to standard of care lomustine for the treatment of patients with glioblastoma that has come…
- Trial name
- NCT06325683
- Testing
- Biopsy Procedure, Biospecimen Collection, Lomustine
- Where
- 325 sites in United States
- Volunteers
- 184 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer
The purpose of this study is to investigate safety of experimental medication BMS-986242 and Nivolumab in patients with advanced cancers.
- Trial name
- NCT03351231
- Testing
- BMS-986242, Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Non-small Cell Lung Cancer
The Impact of Probiotic on Survival and Treatment Response in Metastatic Non-small Cell Lung Cancer Patients
The aim of this study is to evaluate the effect of a probiotic supplement containing Bifidobacterium animalis lactis BL-04 on the clinical effectiveness of immunotherapy in patients diagnosed with metastatic non-small cell lung…
- Trial name
- NCT06428422
- Testing
- Bifidobacterium animalis subsp. lactis Bl-04, Plasebo
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Necmettin Erbakan University
Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non Small Cell Lung Cancer
Emulation of the CheckMate 017/057 (NCT01642004 and NCT01673867) Trials Using Specialty Oncology Electronic Health Records Databases
Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials.
- Trial name
- NCT07485166
- Testing
- Initiation of nivolumab, Initiation of docetaxel
- Where
- United States
- Volunteers
- 810 people
- Sponsor
- Brigham and Women's Hospital
Melanoma, Melanoma Stage III
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
The main purpose of this study is to compare the efficacy of bempegaldesleukin plus nivolumab versus nivolumab in patients with completely resected Stage IIIA/B/C/D, or Stage IV cutaneous melanoma who are at high risk for…
- Conditions
- Melanoma, Melanoma Stage III, Melanoma Stage IV, Melanoma (Skin)
- Trial name
- PIVOT-12 (NCT04410445)
- Testing
- Bempegaldesleukin, Nivolumab
- Where
- 212 sites in United States, Australia and 15 more
- Volunteers
- 765 people
- Sponsor
- Nektar Therapeutics
Mucosal Melanoma
Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma
This is a single arm phase II clinical trial of Ipilimumab and Nivolumab in patients with resected mucosal melanoma. Ipilimumab (1 mg/kg) and Nivolumab (3 mg/kg) will be administered Day 1 of a 21-day cycle in Cycles 1-4 and then…
- Trial name
- NCT03241186
- Testing
- Ipilimumab, Nivolumab
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Robert R. McWilliams, MD
Melanoma
Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients
To improve the efficacy of immunotherapy for cancer, recent studies focused on specific targets to redirect the immune network toward eradicating a variety of tumors and ameliorating the self-destructive process.
- Trial name
- Nivo-TIL (NCT03374839)
- Testing
- TIL + IL-2 + Nivolumab
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Nantes University Hospital
Metastatic Melanoma
PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma
The purpose of this research is to test the safety and effectiveness of the investigational combination of anti-Programmed Death (PD)-1 antibody therapy with or without LAG-3 inhibition (pembrolizumab or nivolumab+relatlimab) and…
- Trial name
- NCT05034536
- Testing
- Pembrolizumab, Infliximab, Relatlimab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Massachusetts General Hospital
Hepatocellular Carcinoma, Anti-PD1 Antibody
Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma
For the advanced hepatocellular carcinoma (HCC), the targeted therapy and immunotherapy are recommended. This study focused on the management of Lenvatinib combined anti-PD1 antibody for the HCC.
- Conditions
- Hepatocellular Carcinoma, Anti-PD1 Antibody, Liver Diseases
- Trial name
- NCT04627012
- Testing
- Lenvatinib, Opdivo, Camrelizumab
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Renal Cell, Head and Neck Neoplasm
Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
This is a Phase 2, non-randomised, open-label, multicentric study to investigate the efficacy and safety of nivolumab monotherapy in 6 cohorts of patients with specific rare cancers who have unresectable locally advanced or…
- Conditions
- Carcinoma, Renal Cell, Head and Neck Neoplasm, Skin Neoplasms, Microsatellite Instability
- Trial name
- AcSé (NCT03012581)
- Testing
- Nivolumab
- Where
- France
- Volunteers
- 269 people
- Sponsor
- UNICANCER
Gastric Cancer/Adenocarcinoma of Esophagogastric Junction
A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer
This is an open-label, single-arm, single-center clinical study to investigate the safety and efficacy of fuquinitinib combined with PD-1 inhibitors and first-line chemotherapy in the treatment of inoperable HER2-negative…
- Trial name
- G/GEJ cancer (NCT06158919)
- Testing
- Fruquintinib、Nivolumab、Sintilimab、Oxaliplatin、Teysuno、Capecitabine
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Fudan University
Lung Cancer, Mesothelioma
Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung Cancer
This research is being done to study the safety and feasibility of implanting and retrieving a microdevice that releases microdoses of 20 specific drugs or drug combinations as a possible tool to evaluate the effectiveness of…
- Conditions
- Lung Cancer, Mesothelioma, Suspected Lung Cancer, Suspected Mesothelioma
- Trial name
- NCT07892300
- Testing
- Implantable Micro- drug delivery Microdevice (IMD)
- Volunteers
- 20 people
- Sponsor
- Oliver Jonas
Gastric Cancer, Gastroesophageal Junction Cancer
A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.
The main objectives of this study are to evaluate the safety and tolerability of bemarituzumab in combination with other anti-cancer therapies, and to evaluate the efficacy of bemarituzumab in combination with S-1 and oxaliplatin…
- Trial name
- FORTITUDE-103 (NCT05322577)
- Testing
- Bemarituzumab, CAPOX, SOX
- Where
- 42 sites in United States, Japan and 3 more
- Volunteers
- 72 people
- Sponsor
- Amgen
Metastatic Gastric Cancer, PD-L1 Gene Amplification
Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer
The goal of this phase 2 clinical trial is to evaluate the efficacy of nivolumab in combination with CAPOX in patients with FGFR2-positive/PD-L1-positive/HER2-negative metastatic gastric cancer.
- Conditions
- Metastatic Gastric Cancer, PD-L1 Gene Amplification, FGFR2 Amplification
- Trial name
- NIVOFGFR2 (NCT05859477)
- Testing
- Nivolumab, Capecitabine, Oxaliplatin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Kidney Cancer Research Bureau
Non-Small Cell Lung Cancer Metastatic
Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr
Non Small Cell lung cancer (NSCLC) remains the first cause of death by cancer in the World. For the patients presenting a NSCLC stage IV, the median of survival is about 15 months today.
- Trial name
- DICIPLE (NCT03469960)
- Testing
- Ipilimumab, Nivolumab
- Where
- 47 sites in France
- Volunteers
- 265 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Pancreatic Adenocarcinoma
Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.
- Trial name
- NCT03080974
- Testing
- Nivolumab, Irreversible Electroporation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Louisville
Head and Neck Squamous Cell Carcinoma
Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC
This trial aims to evaluate whether the addition of anti-PD-1 antibody to adjuvant postoperative chemoradiotherapy could improve disease free survival in patients with high-risk locally advanced head and neck squamous cell…
- Trial name
- NCT06170710
- Testing
- Anti-PD-1 monoclonal antibody, Postoperative CCRT
- Where
- China
- Volunteers
- 173 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Melanoma
A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US
The goal of this study is to describe patient characteristics, treatment outcomes and adverse events for patients with metastatic melanoma testing positive for PD-L1 expression treated first line (1L) with either nivolumab and…
- Trial name
- NCT03732560
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Melanoma
Radiation and Combination Immunotherapy for Melanoma
This is a Phase 2 study designed to evaluate the combination of checkpoint blockade and aldesleukin (IL-2) therapy after a course of standard of care palliative radiation in the management of unresectable metastatic melanoma.
- Trial name
- NCT03850691
- Testing
- Aldesleukin: All Patients, Nivolumab: Cohort 1 (Cutaneous), Nivolumab: Cohort 2 (Ocular)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Masonic Cancer Center, University of Minnesota